RU2009141359A - Посттерапевтический прогноз выживания больных раком с использованием микрорнк - Google Patents
Посттерапевтический прогноз выживания больных раком с использованием микрорнк Download PDFInfo
- Publication number
- RU2009141359A RU2009141359A RU2009141359/14A RU2009141359A RU2009141359A RU 2009141359 A RU2009141359 A RU 2009141359A RU 2009141359/14 A RU2009141359/14 A RU 2009141359/14A RU 2009141359 A RU2009141359 A RU 2009141359A RU 2009141359 A RU2009141359 A RU 2009141359A
- Authority
- RU
- Russia
- Prior art keywords
- hsa
- patient
- expression level
- post
- mir372
- Prior art date
Links
- 230000004083 survival effect Effects 0.000 title claims abstract 27
- 206010028980 Neoplasm Diseases 0.000 title claims abstract 15
- 201000011510 cancer Diseases 0.000 title claims abstract 15
- 108091070501 miRNA Proteins 0.000 title claims abstract 10
- 238000000034 method Methods 0.000 claims abstract 35
- 108091068985 Homo sapiens miR-137 stem-loop Proteins 0.000 claims abstract 21
- 108091067572 Homo sapiens miR-221 stem-loop Proteins 0.000 claims abstract 21
- 108091067570 Homo sapiens miR-372 stem-loop Proteins 0.000 claims abstract 21
- 108091067627 Homo sapiens miR-182 stem-loop Proteins 0.000 claims abstract 18
- 239000002679 microRNA Substances 0.000 claims abstract 12
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims abstract 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims abstract 6
- 108700011259 MicroRNAs Proteins 0.000 claims abstract 5
- 108091091807 let-7a stem-loop Proteins 0.000 claims abstract 5
- 108091057746 let-7a-4 stem-loop Proteins 0.000 claims abstract 5
- 108091028376 let-7a-5 stem-loop Proteins 0.000 claims abstract 5
- 108091024393 let-7a-6 stem-loop Proteins 0.000 claims abstract 5
- 108091091174 let-7a-7 stem-loop Proteins 0.000 claims abstract 5
- 206010006187 Breast cancer Diseases 0.000 claims abstract 3
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract 3
- 206010009944 Colon cancer Diseases 0.000 claims abstract 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract 3
- 208000009956 adenocarcinoma Diseases 0.000 claims abstract 3
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims abstract 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims abstract 3
- 208000032839 leukemia Diseases 0.000 claims abstract 3
- 201000005202 lung cancer Diseases 0.000 claims abstract 3
- 208000020816 lung neoplasm Diseases 0.000 claims abstract 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims abstract 3
- 201000002528 pancreatic cancer Diseases 0.000 claims abstract 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims abstract 3
- 238000001959 radiotherapy Methods 0.000 claims abstract 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims abstract 3
- 239000000126 substance Substances 0.000 claims abstract 3
- 238000001356 surgical procedure Methods 0.000 claims abstract 3
- 108091034117 Oligonucleotide Proteins 0.000 claims 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91099307P | 2007-04-10 | 2007-04-10 | |
| US60/910,993 | 2007-04-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2009141359A true RU2009141359A (ru) | 2011-05-20 |
Family
ID=39831416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009141359/14A RU2009141359A (ru) | 2007-04-10 | 2008-04-09 | Посттерапевтический прогноз выживания больных раком с использованием микрорнк |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7745134B2 (https=) |
| EP (1) | EP2134874A4 (https=) |
| JP (1) | JP2010523156A (https=) |
| KR (1) | KR20100027102A (https=) |
| CN (1) | CN101688240A (https=) |
| AU (1) | AU2008237036A1 (https=) |
| CA (1) | CA2695868A1 (https=) |
| CO (1) | CO6231056A2 (https=) |
| IL (1) | IL201298A0 (https=) |
| MX (1) | MX2009010899A (https=) |
| RU (1) | RU2009141359A (https=) |
| TW (1) | TWI367949B (https=) |
| WO (1) | WO2008124777A1 (https=) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103820562B (zh) | 2005-08-01 | 2015-05-13 | 俄亥俄州立大学研究基金会 | 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物 |
| JP2009507918A (ja) | 2005-09-12 | 2009-02-26 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | Ｂｃｌ２関連癌の診断及び療法のための組成物及び方法 |
| EP1969147B1 (en) | 2006-01-05 | 2014-07-30 | The Ohio State University Research Foundation | microRNA-based methods for the diagnosis of stomach cancer |
| ES2553442T3 (es) | 2006-01-05 | 2015-12-09 | The Ohio State University Research Foundation | Procedimientos basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón |
| US7670840B2 (en) | 2006-01-05 | 2010-03-02 | The Ohio State University Research Foundation | Micro-RNA expression abnormalities of pancreatic, endocrine and acinar tumors |
| EP2369011A1 (en) | 2006-03-20 | 2011-09-28 | The Ohio State University Research Foundation | Microrna fingerprints during human megakaryocytopoiesis |
| EP2041317A4 (en) | 2006-07-13 | 2009-10-14 | Univ Ohio State Res Found | METHODS AND COMPOSITIONS BASED ON MICRO-RNA FOR THE DIAGNOSIS AND TREATMENT OF COLON CANCER RELATED DISEASES |
| EP2061907B1 (en) | 2006-09-19 | 2011-11-23 | The Ohio State University Research Foundation | Tcl1 expression in chronic lymphocytic leukemia (cll) regulated by mir-29 and mir-181 |
| US8252538B2 (en) | 2006-11-01 | 2012-08-28 | The Ohio State University | MicroRNA expression signature for predicting survival and metastases in hepatocellular carcinoma |
| WO2008094545A2 (en) | 2007-01-31 | 2008-08-07 | The Ohio State University Research Foundation | Mic orna-based methods and compositions for the treatment of acute myeloid leukemia |
| ES2537349T3 (es) * | 2007-06-08 | 2015-06-05 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Métodos para determinar un subtipo de carcinoma hepatocelular |
| CN101918424A (zh) | 2007-06-15 | 2010-12-15 | 俄亥俄州立大学研究基金会 | 用于靶向由Drosha介导的微小RNA加工的致癌ALL-1融合蛋白 |
| CN101809169B (zh) | 2007-07-31 | 2013-07-17 | 俄亥俄州立大学研究基金会 | 通过靶向dnmt3a和dnmt3b恢复甲基化的方法 |
| EP2653561B1 (en) | 2007-08-03 | 2016-03-02 | The Ohio State University Research Foundation | Ultraconserved regions encoding ncRNAs |
| EP3028708A1 (en) | 2007-08-22 | 2016-06-08 | The Ohio State University Research Foundation | Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias |
| CA2703707A1 (en) | 2007-10-26 | 2009-04-30 | The Ohio State University Research Foundation | Methods for identifying fragile histidine triad (fhit) interaction and uses thereof |
| EP2307028B1 (en) | 2008-06-11 | 2013-10-02 | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services | Use of mir-26 family as a predictive marker of hepatocellular carcinoma and responsiveness to therapy |
| WO2010054386A2 (en) * | 2008-11-10 | 2010-05-14 | Battelle Memorial Institute | Methods, compositions, and devices utilizing microrna to determine physiological conditions |
| US8729041B2 (en) | 2008-12-03 | 2014-05-20 | The Johns Hopkins University | Compositions and methods for treating hepatic neoplasia |
| EP2196543A1 (en) * | 2008-12-15 | 2010-06-16 | Koninklijke Philips Electronics N.V. | Compositions and methods for micro-rna expression profiling of hepatocellular cancer |
| CN102272330B (zh) * | 2009-02-23 | 2014-04-23 | 博奥生物有限公司 | 用于肺癌诊断、预后和提高生存率的试剂盒 |
| CN101638656B (zh) * | 2009-08-28 | 2011-05-11 | 南京医科大学 | 一种与非小细胞肺癌预后相关的血清/血浆miRNA标志物及其应用 |
| AU2010321555B2 (en) | 2009-11-23 | 2015-10-15 | The Ohio State University | Materials and methods useful for affecting tumor cell growth, migration and invasion |
| JP5763098B2 (ja) * | 2009-12-20 | 2015-08-12 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
| US20110223607A1 (en) | 2010-03-12 | 2011-09-15 | Quest Diagnostics Investments Incorporated | Circulating microrna as a marker for hepatocellular carcinoma |
| ES2606146T3 (es) | 2010-11-12 | 2017-03-22 | The Ohio State University Research Foundation | Métodos relacionados con microARN-21 y reparación de desapareamiento en cáncer colorrectal |
| CN103313706A (zh) | 2010-11-15 | 2013-09-18 | 俄亥俄州立大学研究基金会 | 控制释放粘膜粘合系统 |
| US8664192B2 (en) | 2011-03-07 | 2014-03-04 | The Ohio State University | Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer |
| US8404437B2 (en) | 2011-03-29 | 2013-03-26 | Taipei Veterans General Hospital | MicroRNA as a cancer progression predictor and its use for treating cancer |
| WO2012151212A1 (en) * | 2011-05-01 | 2012-11-08 | University Of Rochester | Multifocal hepatocellular carcinoma microrna expression patterns and uses thereof |
| WO2013038737A1 (ja) | 2011-09-16 | 2013-03-21 | 北海道公立大学法人 札幌医科大学 | 膀胱癌細胞の検出方法、膀胱癌細胞の検出方法に用いるプライマー及び膀胱癌マーカ |
| EP2766500A4 (en) | 2011-10-14 | 2015-10-14 | Univ Ohio State | METHOD AND MATERIALS IN CONNECTION WITH EGG CANCER |
| AU2012352265B2 (en) | 2011-12-13 | 2017-02-16 | Ohio State Innovation Foundation | Methods and compositions related to miR-21 and miR-29a, exosome inhibition, and cancer metastasis |
| CA2859021A1 (en) * | 2011-12-19 | 2013-06-27 | Valley Health System | Methods and kits for detecting subjects at risk of having cancer |
| US8859202B2 (en) | 2012-01-20 | 2014-10-14 | The Ohio State University | Breast cancer biomarker signatures for invasiveness and prognosis |
| US8846316B2 (en) | 2012-04-30 | 2014-09-30 | Industrial Technology Research Institute | Biomarker for human liver cancer |
| US10738363B2 (en) | 2016-08-31 | 2020-08-11 | National Central University | Analyzer and analytical method for predicting prognosis of cancer radiotherapy |
| DE102018110526A1 (de) | 2018-05-02 | 2019-11-07 | Faurecia Autositze Gmbh | Verfahren zur Montage eines Linearaktuators für einen Kraftfahrzeugsitz |
| CN108630317B (zh) * | 2018-05-09 | 2022-04-15 | 中国科学院昆明动物研究所 | 一种基于多基因表达特征谱的肝癌个性化预后评估方法 |
| CN108320806B (zh) * | 2018-05-09 | 2022-04-12 | 中国科学院昆明动物研究所 | 一种基于多基因表达特征谱的结肠癌个性化预后评估方法 |
| CN108647493B (zh) * | 2018-05-09 | 2022-01-18 | 中国科学院昆明动物研究所 | 一种肾透明细胞癌个性化预后评估方法 |
| CN108648826B (zh) * | 2018-05-09 | 2022-04-15 | 中国科学院昆明动物研究所 | 一种基于多基因表达特征谱的胰腺癌个性化预后评估方法 |
| CN108470111B (zh) * | 2018-05-09 | 2022-01-18 | 中国科学院昆明动物研究所 | 一种基于多基因表达特征谱的胃癌个性化预后评估方法 |
| CN108733980B (zh) * | 2018-05-09 | 2022-01-18 | 中国科学院昆明动物研究所 | 基于多基因表达特征谱胶质母细胞瘤个性化预后评估方法 |
| CN108363907B (zh) * | 2018-05-09 | 2022-01-18 | 中国科学院昆明动物研究所 | 一种基于多基因表达特征谱的肺腺癌个性化预后评估方法 |
| CN108611416B (zh) * | 2018-05-09 | 2020-12-29 | 中国科学院昆明动物研究所 | 一种基于多基因表达特征谱的宫颈癌个性化预后评估方法 |
| US11410745B2 (en) * | 2018-06-18 | 2022-08-09 | International Business Machines Corporation | Determining potential cancer therapeutic targets by joint modeling of survival events |
| TWI758670B (zh) * | 2018-12-24 | 2022-03-21 | 奎克生技光電股份有限公司 | 健康風險評估方法 |
| CN111172285A (zh) * | 2020-02-26 | 2020-05-19 | 江南大学附属医院 | 用于胰腺癌早期诊断和/或预后监测的miRNA组及其应用 |
| TWI878107B (zh) * | 2024-04-30 | 2025-03-21 | 朱旆億 | 乳癌預後存活率預測模型建立方法及系統 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ538982A (en) | 2002-09-27 | 2008-07-31 | Oridis Biomed Forschungs Und E | Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis or treatment of liver disorders and epithelial cancer |
| CA2504605C (en) | 2002-11-13 | 2016-01-19 | Thomas Jefferson University | Treatment of chronic lymphocytic leukemia and prostate cancer with microrna mir15 |
| CA2554818A1 (en) | 2004-02-09 | 2005-08-25 | Thomas Jefferson University | Diagnosis and treatment of cancers with microrna located in or near cancer-associated chromosomal features |
| US20050272067A1 (en) | 2004-03-10 | 2005-12-08 | Macina Roberto A | Compositions, splice variants and methods relating to cancer specific genes and proteins |
| US20060078913A1 (en) | 2004-07-16 | 2006-04-13 | Macina Roberto A | Compositions, splice variants and methods relating to cancer specific genes and proteins |
| US20070065844A1 (en) | 2005-06-08 | 2007-03-22 | Massachusetts Institute Of Technology | Solution-based methods for RNA expression profiling |
-
2008
- 2008-04-09 KR KR1020097023492A patent/KR20100027102A/ko not_active Withdrawn
- 2008-04-09 TW TW097112898A patent/TWI367949B/zh not_active IP Right Cessation
- 2008-04-09 MX MX2009010899A patent/MX2009010899A/es not_active Application Discontinuation
- 2008-04-09 EP EP08745383A patent/EP2134874A4/en not_active Withdrawn
- 2008-04-09 RU RU2009141359/14A patent/RU2009141359A/ru not_active Application Discontinuation
- 2008-04-09 US US12/100,113 patent/US7745134B2/en not_active Expired - Fee Related
- 2008-04-09 WO PCT/US2008/059767 patent/WO2008124777A1/en not_active Ceased
- 2008-04-09 CA CA2695868A patent/CA2695868A1/en not_active Abandoned
- 2008-04-09 CN CN200880011562A patent/CN101688240A/zh active Pending
- 2008-04-09 AU AU2008237036A patent/AU2008237036A1/en not_active Abandoned
- 2008-04-09 JP JP2010503183A patent/JP2010523156A/ja not_active Withdrawn
-
2009
- 2009-10-01 IL IL201298A patent/IL201298A0/en unknown
- 2009-10-08 CO CO09111661A patent/CO6231056A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CO6231056A2 (es) | 2010-12-20 |
| CA2695868A1 (en) | 2008-10-16 |
| WO2008124777A1 (en) | 2008-10-16 |
| TWI367949B (en) | 2012-07-11 |
| AU2008237036A2 (en) | 2010-09-09 |
| MX2009010899A (es) | 2010-02-17 |
| EP2134874A1 (en) | 2009-12-23 |
| JP2010523156A (ja) | 2010-07-15 |
| EP2134874A4 (en) | 2010-12-22 |
| US7745134B2 (en) | 2010-06-29 |
| IL201298A0 (en) | 2010-05-31 |
| KR20100027102A (ko) | 2010-03-10 |
| CN101688240A (zh) | 2010-03-31 |
| AU2008237036A1 (en) | 2008-10-16 |
| US20080254473A1 (en) | 2008-10-16 |
| TW200912002A (en) | 2009-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2009141359A (ru) | Посттерапевтический прогноз выживания больных раком с использованием микрорнк | |
| Giráldez et al. | Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study | |
| US9745630B2 (en) | MiRNA fingerprint in the diagnosis of prostate cancer | |
| Shrivastava et al. | Up‐regulation of circulating miR‐20a is correlated with hepatitis C virus‐mediated liver disease progression | |
| Busacca et al. | MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications | |
| Motoyama et al. | Over-and under-expressed microRNAs in human colorectal cancer | |
| ES2642395T3 (es) | Huella del miARN en el diagnostico de cáncer de pulmón | |
| Mairinger et al. | Different micro-RNA expression profiles distinguish subtypes of neuroendocrine tumors of the lung: results of a profiling study | |
| Weissmann-Brenner et al. | Tumor microRNA-29a expression and the risk of recurrence in stage II colon cancer | |
| CN101921760B (zh) | 一种与乳腺癌相关的血清/血浆miRNA标志物及其应用 | |
| US20120219958A1 (en) | MicroRNA Signatures Differentiating Uterine and Ovarian Papillary Serous Tumors | |
| Reshmi et al. | Beyond HPV: oncomirs as new players in cervical cancer | |
| AU2011311881A1 (en) | MicroRNAs (miRNA) as biomakers for the identification of familial and non-familial colorectal cancer | |
| Soga et al. | microRNA expression profiles in oral squamous cell carcinoma | |
| EP3276009B1 (en) | Microrna expression markers for crc development | |
| Guo et al. | Identification of miRNAs that are associated with tumor metastasis in neuroblastoma | |
| Chen et al. | Circulating miR-148b-3p and miR-409-3p as biomarkers for heart failure in patients with mitral regurgitation | |
| Venza et al. | Identification of microRNA expression patterns in cutaneous and uveal melanoma cell lines | |
| Naeini et al. | Noncoding RNAs and cancer | |
| MX2010012542A (es) | Metodos para evaluar el cancer colorrectal y composiciones para usar en el. | |
| Hubaux et al. | MicroRNAs as biomarkers for clinical features of lung cancer | |
| Zheng et al. | MircoRNA-629 promotes proliferation, invasion and migration of nasopharyngeal carcinoma through targeting PDCD4. | |
| WO2011014083A3 (en) | Determination of the risk of distant metastases in surgically treated patients with non-small cell lung cancer in stage i-iiia | |
| KR20170021580A (ko) | 폐암의 바이오마커 | |
| Ozen et al. | MicroRNAs in Human Prostate Cancer: From Pathogenesis to Therapeutic Implications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20110410 |